Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19929585 | 0.94 | HPGD (0.49) | ALBLMNATSHRL3MBTL1SLC5A1 | |
| SCHEMBL26548503 | 0.88 | ALB (0.41) | ALBLMNAPKMSLC5A1 | |
| SCHEMBL19929575 | 0.88 | ALB (0.53) | ALBLMNAPKMTSHRL3MBTL1 | |
| SCHEMBL19929579 | 0.88 | ALB (0.53) | ALBLMNAPKMTSHRL3MBTL1 | |
| SCHEMBL16016336 | 0.88 | ALB (0.68) | ALBLMNAPKMTSHRL3MBTL1 | |
| SCHEMBL24253361 | 0.88 | ALB (0.56) | ALBLMNAPKMTSHRL3MBTL1 | |
| SCHEMBL19011013 | 0.88 | ALB (0.56) | ALBLMNAPKMTSHRL3MBTL1 | |
| SCHEMBL19929578 | 0.88 | ALB (0.53) | ALBLMNAPKMTSHRL3MBTL1 | |
| SCHEMBL19011014 | 0.88 | ALB (0.68) | ALBLMNAPKMTSHRL3MBTL1 | |
| SCHEMBL19929574 | 0.85 | ALB (0.56) | ALBLMNAPKMTSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20180066298-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IL1RN, IL2RA, IL1A | ALB 31/4885LMNA 2979/4885PKM 4669/4885 |
| US-20180066298-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IL1RN, IL2RA, IL1A | ALB 31/4885LMNA 2979/4885PKM 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.